RenovoRx (NASDAQ:RNXT) CMO Acquires $46,500.00 in Stock

Key Points

  • RenovoRx CMO Ramtin Agah bought 50,000 shares for $46,500 at an average price of $0.93, increasing his direct holdings to 848,460 shares.
  • The company reported quarterly EPS of -$0.07, missing estimates by $0.01, while revenue of $1.07 million slightly exceeded forecasts.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $8.50; ratings range from Strong Buy to Sell.

RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) CMO Ramtin Agah acquired 50,000 shares of the firm's stock in a transaction dated Monday, November 16th. The stock was bought at an average price of $0.93 per share, with a total value of $46,500.00. Following the acquisition, the chief marketing officer directly owned 848,460 shares in the company, valued at $789,067.80. This represents a 6.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

RenovoRx Stock Up 8.9%

NASDAQ:RNXT opened at $1.04 on Wednesday. The stock's 50-day simple moving average is $1.40 and its 200 day simple moving average is $1.11. RenovoRx, Inc. has a 52-week low of $0.73 and a 52-week high of $2.59.

RenovoRx (NASDAQ:RNXT - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). RenovoRx had a negative net margin of 469.02% and a negative return on equity of 133.49%. The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.06 million. On average, analysts expect that RenovoRx, Inc. will post -0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth




RNXT has been the topic of a number of analyst reports. Weiss Ratings upgraded RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 2nd. Wall Street Zen cut shares of RenovoRx from a "hold" rating to a "sell" rating in a research note on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.50.

Get Our Latest Research Report on RNXT

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Cetera Investment Advisers raised its holdings in shares of RenovoRx by 205.1% in the 3rd quarter. Cetera Investment Advisers now owns 57,976 shares of the company's stock valued at $90,000 after purchasing an additional 38,976 shares during the period. T3 Companies LLC bought a new position in RenovoRx during the third quarter worth about $151,000. Finally, State Street Corp increased its position in RenovoRx by 501.6% during the third quarter. State Street Corp now owns 314,636 shares of the company's stock worth $491,000 after buying an additional 262,332 shares during the last quarter. 3.10% of the stock is currently owned by institutional investors and hedge funds.

About RenovoRx

(Get Free Report)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company's platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

Read More

Insider Buying and Selling by Quarter for RenovoRx (NASDAQ:RNXT)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at RenovoRx?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for RenovoRx and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles